PAULO SERGIO MARTINS DE ALCANTARA

(Fonte: Lattes)
Índice h a partir de 2011
13
Lattes
Projetos de Pesquisa
Unidades Organizacionais
DVCLCIR-62, Hospital Universitário
LIM/26 - Laboratório de Pesquisa em Cirurgia Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: ALEXANDRE FERREIRA RAMOS ×

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 22 Citação(ões) na Scopus
    Myokines in treatment-na & iuml;ve patients with cancer-associated cachexia
    (2021) CASTRO, Gabriela S. de; CORREIA-LIMA, Joanna; SIMOES, Estefania; ORSSO, Camila E.; XIAO, Jingjie; GAMA, Leonardo R.; GOMES, Silvio P.; GONCALVES, Daniela Caetano; COSTA, Raquel G. F.; RADLOFF, Katrin; LENZ, Ulrike; TARANKO, Anna E.; BIN, Fang Chia; FORMIGA, Fernanda B.; GODOY, Louisie G. L. de; SOUZA, Rafael P. de; NUCCI, Luis H. A.; FEITOZA, Mario; CASTRO, Claudio C. de; TOKESHI, Flavio; ALCANTARA, Paulo S. M.; OTOCH, Jose P.; RAMOS, Alexandre F.; LAVIANO, Alessandro; COLETTI, Dario; MAZURAK, Vera C.; PRADO, Carla M.; SEELAENDER, Marilia
    Cancer-associated cachexia is a complex metabolic syndrome characterized by weight loss and systemic inflammation. Muscle loss and fatty infiltration into muscle are associated with poor prognosis in cancer patients. Skeletal muscle secretes myokines, factors with autocrine, paracrine and/or endocrine action, which may be modified by or play a role in cachexia. This study examined myokine content in the plasma, skeletal muscle and tumor homogenates from treatment-na & iuml;ve patients with gastric or colorectal stages I-IV cancer with cachexia (CC, N = 62), or not (weight stable cancer, WSC, N = 32). Myostatin, interleukin (IL) 15, follistatin-like protein 1 (FSTL-1), fatty acid binding protein 3 (FABP3), irisin and brain-derived neurotrophic factor (BDNF) protein content in samples was measured with Multiplex technology; body composition and muscle lipid infiltration were evaluated in computed tomography, and quantification of triacylglycerol (TAG) in the skeletal muscle. Cachectic patients presented lower muscle FSTL-1 expression (p = 0.047), higher FABP3 plasma content (p = 0.0301) and higher tumor tissue expression of FABP3 (p = 0.0182), IL-15 (p = 0.007) and irisin (p = 0.0110), compared to WSC. Neither muscle TAG content, nor muscle attenuation were different between weight stable and cachectic patients. Lumbar adipose tissue (AT) index, visceral AT index and subcutaneous AT index were lower in CC (p = 0.0149, p = 0.0455 and p = 0.0087, respectively), who also presented lower muscularity in the cohort (69.2% of patients; p = 0.0301), compared to WSC. The results indicate the myokine profile in skeletal muscle, plasma and tumor is impacted by cachexia. These findings show that myokines eventually affecting muscle wasting may not solely derive from the muscle itself (as the tumor also may contribute to the systemic scenario), and put forward new perspectives on cachexia treatment targeting myokines and associated receptors and pathways. (c) 2020 The Author(s).